List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons

    SBC: SensoDX II, LLC            Topic: NIDA

    Abstract Opioid abuse disorderOADaffectsmillion of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortalityIn addition to its enormous social impactOAD carries a multi billion dollar price tag that includes $billionspecifically for health care and other costs related to prescription opioid abuse and misuseAlthough effective interventions exis ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Resveratrol as a Corneal Pain Therapeutic

    SBC: TED'S BRAIN SCIENCE INCORPORATED            Topic: N

    More thanindividuals undergo laser vision correction surgery each year in the United Statesincluding laser assisted in situ keratomileusisLASIKand photorefractive keratectomyPRKThese procedures damage the nerves in the corneal epithelium causing intense acute pain that most patients rate as greater thanon ascalemany report the pain to beunbearableeven after analgesic treatmentWhile virtually all p ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management

    SBC: RH NANOPHARMACEUTICALS L.L.C.            Topic: 102

    SUMMARYThe White House has initiated an aggressive campaign to combat the current opioid crisis that is affecting all levels of the American way of lifeThe opioid crisis has emerged from multiple frontsAmong these various frontsthe continued use of opioids in the post operative area is a growing addiction riskCurrent postoperative pain management utilizes a multimodal pain management strategywhich ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine

    SBC: Neurotrope Bioscience, Inc.            Topic: R

    Program Director Principal InvestigatorLastFirstMiddleMiao Kun Sun Project Summary Abstract The importance of memory impairment and dementiasincluding Alzheimer s diseaseADas a global priority has been well recognizedMany compounds that target AD pathologies have been developed preclinically but have failed in clinical trialsmostly for the lack of therapeutic efficaciesNeurotrope Bioscience Incis ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid and Effective Localized Neurovascular Cooling Using the Khione Insulative Catheter

    SBC: Tom L Merrill            Topic: 101

    Project Summary Stroke is theth leading cause of death and number one cause of adult disability in the United StatesThe primary goal of acute ischemic strokeAIStreatment is quickly restoring blood perfusionHoweverstudies have shown that this return of blood flowwhile necessarycan also cause damage to local tissue leading to poor patient outcomesTherapeutic hypothermiaTHhas been shown to be a robus ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Screen molecules modulating MOR trafficking with a newly developed MOR/14-3-3 bioassay.

    SBC: BIOINVENU CORPORATION            Topic: NIDA

    Specific AimValidate the MORLinkLight assay with a pilot HTS to identify molecules modulating MOR traffickingSignificanceThe current crisis of opioid use disordersOUDsand opioid overdose deaths in the United States urgently demands safer and better therapeuticsTo develop better and safer therapeutic agents for the treatment of OUDsfirst and foremost is to have new bioassays which are different fro ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Transcutaneous auricular neurostimulation for neonatal abstinence syndrome

    SBC: SPARK BIOMEDICAL INC            Topic: R43

    Neonatal abstinence syndromeNASis a condition in which infants undergo withdrawal after exposure to prescription or non prescription opioids such as methadone or heroin in uteroNAS babies exhibit hyperirritability of the central nervous system and respiratorygastrointestinaland autonomic symptomsThese symptoms usually appear withintohours after birthAs ofan infant with NAS was born everyminutes in ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Strategies for Development of a Multiplexed Test with Expanded Content for Spinal Muscular Atrophy

    SBC: ASURAGEN, INC.            Topic: 102

    SummaryThe overall goal of this project is to develop a cost effective multiplexed diagnostic test for spinal muscular atrophySMAto rapidly and accurately analyze multiple classes of disease causingdisease modifying DNA variantsand carrier status markersUltimatelythe proposed test will have a far reaching impact by expanding the identification and stratification of patients who may benefit from ne ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a rapid diagnostic assay for Myasthenia Gravis

    SBC: Attogene Corporation            Topic: 101

    Project Summary AbstractThe physiological effect of autoantibody binding to the motor endplate junction nicotinic acetylcholine receptorsAchRcauses numerous symptoms associated with Myasthenia GravisMGand is characterized by drooping of one or both eyesblurred or double visionchange in facial expressiondifficulty swallowingshortness of breathimpaired speech and weakness of muscle functionIn some c ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government